Bio News

OrbiMed has raised $3 billion (about 4 trillion won) to invest in biotech and life sciences companies in the United States, Europe and Asia.
OrbiMed Asia Partners Fund VI raised more than $1 billion, making it the firm’s largest fund in the region to date.
OrbiMed plans to use the capital to build leading companies in biopharmaceuticals, medical devices and technology-enabled health care services.

Biobook Team
biobookmedia@biobook.co.krCosentyx Approved by FDA for 11th Indication: Polymyalgia Rheumatica
Delonix and Singapore’s A*STAR IDL to Collaborate on Vaccine Against Drug-Resistant Klebsiella pneumoniae
Brazilian Health Regulatory Agency Approves Oral Plaque Psoriasis Treatment Icotyde
Medtronic to Acquire Contego Medical for $380 Million
Brazilian Health Regulatory Agency Approves Botox for Masseter Muscle Prominence
Roche’s oral SERD Itovebi wins FDA approval, cutting risk of progression by 62%